DE69113148T2 - Thioxo-Heterocyclen und ihre pharmazeutische Verwendung. - Google Patents

Thioxo-Heterocyclen und ihre pharmazeutische Verwendung.

Info

Publication number
DE69113148T2
DE69113148T2 DE69113148T DE69113148T DE69113148T2 DE 69113148 T2 DE69113148 T2 DE 69113148T2 DE 69113148 T DE69113148 T DE 69113148T DE 69113148 T DE69113148 T DE 69113148T DE 69113148 T2 DE69113148 T2 DE 69113148T2
Authority
DE
Germany
Prior art keywords
formula
group
thioxo
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69113148T
Other languages
German (de)
English (en)
Other versions
DE69113148D1 (de
Inventor
Pierre Andre Raymond Bruneau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca SAS
Syngenta Ltd
Original Assignee
Zeneca Pharma SA
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Pharma SA, Zeneca Ltd filed Critical Zeneca Pharma SA
Application granted granted Critical
Publication of DE69113148D1 publication Critical patent/DE69113148D1/de
Publication of DE69113148T2 publication Critical patent/DE69113148T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
DE69113148T 1990-07-13 1991-07-09 Thioxo-Heterocyclen und ihre pharmazeutische Verwendung. Expired - Fee Related DE69113148T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90402034 1990-07-13
EP91400079 1991-01-15

Publications (2)

Publication Number Publication Date
DE69113148D1 DE69113148D1 (de) 1995-10-26
DE69113148T2 true DE69113148T2 (de) 1996-03-28

Family

ID=26127361

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69113148T Expired - Fee Related DE69113148T2 (de) 1990-07-13 1991-07-09 Thioxo-Heterocyclen und ihre pharmazeutische Verwendung.

Country Status (22)

Country Link
US (1) US5240941A (enExample)
EP (1) EP0466452B1 (enExample)
JP (1) JPH04243877A (enExample)
KR (1) KR920002561A (enExample)
AT (1) ATE128133T1 (enExample)
AU (1) AU638579B2 (enExample)
CA (1) CA2046006A1 (enExample)
CS (1) CS214891A3 (enExample)
DE (1) DE69113148T2 (enExample)
DK (1) DK0466452T3 (enExample)
ES (1) ES2076472T3 (enExample)
FI (1) FI913369A7 (enExample)
GB (1) GB9113137D0 (enExample)
GR (1) GR3017453T3 (enExample)
HU (1) HUT61999A (enExample)
IE (1) IE912138A1 (enExample)
IL (1) IL98603A0 (enExample)
MX (1) MX174406B (enExample)
NO (1) NO912750L (enExample)
NZ (1) NZ238703A (enExample)
PT (1) PT98292A (enExample)
TW (1) TW235918B (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9018134D0 (en) * 1989-09-29 1990-10-03 Ici Plc Heterocyclic derivatives
IE911853A1 (en) * 1990-06-21 1992-01-01 Ici Plc Heterocyclene derivatives
IE914005A1 (en) * 1990-12-14 1992-06-17 Zeneca Ltd Novel intermediates
GB9122590D0 (en) * 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
AU4444393A (en) * 1992-09-01 1994-03-10 Zeneca Limited Pyrrolidine derivatives
US5354865A (en) * 1992-09-10 1994-10-11 Abbott Laboratories Phenylmethyl derivatives having lipoxygenase inhibitory activity
AP9400632A0 (en) * 1993-04-29 1995-10-07 Zeneca Ltd Ether derivatives.
JPH08511254A (ja) * 1993-06-07 1996-11-26 ゼネカ・リミテッド ２−オキソ−１，２，３，４−テトラヒドロキノリン誘導体
EP0702678A1 (en) * 1993-06-07 1996-03-27 Zeneca Limited Aniline derivatives
US5459271A (en) * 1993-07-20 1995-10-17 Merck Frosst Canada, Inc. Arylbicyclooctanes as inhibitors of leukotriene biosynthesis
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6677364B2 (en) * 1998-04-20 2004-01-13 G.D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
JP2007516258A (ja) 2003-12-12 2007-06-21 ワイス 心臓血管の疾患治療に有用なキノリン誘導体
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP3268085A4 (en) 2015-03-13 2018-10-31 The Board of Trustees of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
SMT202500447T1 (it) 2021-11-02 2026-01-12 Flare Therapeutics Inc Agonisti inversi di pparg e loro usi

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743737A (en) * 1970-05-21 1973-07-03 Smith Kline French Lab 3-sulfonamido-4-hydroxyphenyl-2-piperindinylcarbinol compositions
US3661917A (en) * 1970-05-21 1972-05-09 Smith Kline French Lab 3-sulfonamido-4-hydroxyphenyl-2-piperidylcarbinols
IE56702B1 (en) * 1982-12-01 1991-11-06 Usv Pharma Corp Antiinflammatory antiallergic compounds
NO174506B (no) * 1984-10-30 1994-02-07 Usv Pharma Corp Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4876346A (en) * 1985-05-02 1989-10-24 American Home Products Corporation Quinoline compounds
EP0271287A3 (en) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Quinoline dioic acids and amides
US4920133A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920131A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4918081A (en) * 1988-06-20 1990-04-17 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene d4
EP0349062A1 (en) * 1988-06-27 1990-01-03 Merck Frosst Canada Inc. Quinoline ether alkanoic acid
GB8926981D0 (en) * 1988-12-23 1990-01-17 Ici Plc Heterocyclic derivatives
IE70521B1 (en) * 1989-02-28 1996-12-11 Zeneca Pharma Sa Heterocycles with inhibitory activity of 5-lipoxygenase
GB9018134D0 (en) * 1989-09-29 1990-10-03 Ici Plc Heterocyclic derivatives

Also Published As

Publication number Publication date
HUT61999A (en) 1993-03-29
FI913369A7 (fi) 1992-01-14
EP0466452A2 (en) 1992-01-15
JPH04243877A (ja) 1992-08-31
CS214891A3 (en) 1992-02-19
NO912750L (no) 1992-01-14
US5240941A (en) 1993-08-31
NO912750D0 (no) 1991-07-12
IL98603A0 (en) 1992-07-15
IE912138A1 (en) 1992-01-15
GR3017453T3 (en) 1995-12-31
MX174406B (es) 1994-05-13
EP0466452A3 (en) 1992-08-19
AU638579B2 (en) 1993-07-01
ATE128133T1 (de) 1995-10-15
EP0466452B1 (en) 1995-09-20
ES2076472T3 (es) 1995-11-01
GB9113137D0 (en) 1991-08-07
KR920002561A (ko) 1992-02-28
AU7933791A (en) 1992-01-16
NZ238703A (en) 1994-01-26
FI913369A0 (fi) 1991-07-11
DE69113148D1 (de) 1995-10-26
PT98292A (pt) 1992-05-29
HU912295D0 (en) 1991-12-30
DK0466452T3 (da) 1996-01-02
TW235918B (enExample) 1994-12-11
CA2046006A1 (en) 1992-01-14

Similar Documents

Publication Publication Date Title
DE69114052T2 (de) Bicyclische Pyranderivate und ihre Verwendung als 5-Lipoxygenasehemmer.
DE69011609T2 (de) Heterozyklische Derative.
DE69115134T2 (de) Pyranderivate zur Verwendung als 5-Lipoxygenasehemmer.
DE69024076T2 (de) Heterozyklische Verbindungen mit hemmender Wirkung auf 5-Lipoxygenase
US5240941A (en) Thioxo quinoline compounds, composition and method of use
DE68913940T2 (de) Zyklische Ätherderivate.
DE69011234T2 (de) Diaryläther-Heterozyklen.
DE68913022T2 (de) Heterozyklische Derivate.
DE69026639T2 (de) Heterozyklische zyklische Ether mit hemmender Wirkung auf 5-Lipoxygenase
DE68918680T2 (de) Cycloalkanderivate.
DE69117355T2 (de) Bizyklische Pyran-Derivate und ihre Verwendung als 5-Lipoxygenasehemmer
DE69023940T2 (de) Heterozyklische Zykloalkane mit hemmender Wirkung auf 5-Lipoxygenase.
DE69000438T2 (de) Heterocyclische derivate.
DE69330282T2 (de) Chinolon und acridinon derivate zur behandlung der harninkontinenz
DE3788982T2 (de) Trans-6-[2-(N-heteroaryl)-3,5-disubstituiertes)pyrazol-4-yl)-ethyl] oder -ethenyl]tetrahydro-4-hydroxypyran-2-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE68923860T2 (de) Derivate von Alkoholen und Ethern.
DE69206725T2 (de) Benzolsulfonamidderivate als 5-Lipoxygenasehemmer
DE69018876T2 (de) Pyridazinon-Derivate.
DE69020008T2 (de) Heterozyklische Ether als 5-Lipoxygenase-hemmer.
CH645892A5 (de) Carbostyrilderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende, antihistaminisch wirkende mittel.
DE68916174T2 (de) Mevalonolactone vom Thienopyridin-Typ.
US5288742A (en) α,α dialkylbenzyl derivatives
DE69010795T2 (de) Zyklische Äther von Diaryläther.
DE69408593T2 (de) 4-Aryl-4-Hydroxy-Tetrahydropyrane und 3-Aryl-3-Hydroxy-Tetrahydrofurane als 5-Lipoxygenaseinhibitoren
DE69209099T2 (de) Sulfonamidderivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee